US FDA asks advisory panel to examine dental amalgam safety
This article was originally published in RAJ Devices
The US Food and Drug Administration is asking its external experts to examine several scientific issues that may affect the regulation of dental amalgam, used for direct filling of carious lesions or structural defects in teeth1.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-two guidance documents have been posted on the tracker since its last update.
Italian medicines agency chief Nicola Magrini recounts the problems AIFA faced and the lessons it learned through its work at the height of the coronavirus outbreak in Italy.
EU guidance offers high-level recommendations on the steps that clinical trial sponsors should take to assess the impact of COVID-19 on the quality and reliability of data being generated in ongoing studies. Early scientific advice is recommended if changes must be made to existing protocols or data analysis plans.